Voyager Therapeutics, Inc.
VYGR· Nasdaq
VYGRVoyager Therapeutics, Inc.
Source filing unavailable
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $2.58M | — |
| Net Income | -$14.58M | — |
| EPS Diluted | $15.81 | $6.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
